Oncology News and Research

RSS
New study provides framework for establishing value-based pricing for new cancer drugs

New study provides framework for establishing value-based pricing for new cancer drugs

History of oral contraceptive use influences survival in ovarian cancer patients

History of oral contraceptive use influences survival in ovarian cancer patients

Researchers identify new virus that plays role in rare type of liver cancer

Researchers identify new virus that plays role in rare type of liver cancer

Continuous therapy improves multiple myeloma outcomes

Continuous therapy improves multiple myeloma outcomes

Obesity raises Lynch syndrome CRC risk

Obesity raises Lynch syndrome CRC risk

Nitroglycerin can be repurposed to treat cancer, researchers find

Nitroglycerin can be repurposed to treat cancer, researchers find

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

Researchers find that 26% of senior oncology patients use complementary or alternative medicines

Researchers find that 26% of senior oncology patients use complementary or alternative medicines

ASTRO awards $675,000 to seven physician-researchers to advance radiation oncology research

ASTRO awards $675,000 to seven physician-researchers to advance radiation oncology research

Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder

Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder

Immatics US launched to develop adoptive cellular therapies for treatment of various tumors

Immatics US launched to develop adoptive cellular therapies for treatment of various tumors

UH research points to promising target in treatment of pancreatic cancer

UH research points to promising target in treatment of pancreatic cancer

Lingering cancer-related mutations linked to increased risk of relapse, poor survival in leukemia patients

Lingering cancer-related mutations linked to increased risk of relapse, poor survival in leukemia patients

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

BD Life Sciences completes acquisition of Cellular Research

BD Life Sciences completes acquisition of Cellular Research

Sequenom, UC San Diego Moores Cancer Center collaborate to explore utility of liquid biopsy assay

Sequenom, UC San Diego Moores Cancer Center collaborate to explore utility of liquid biopsy assay

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.